ELDN — Eledon Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1404281 ·
Last close
$2.65
Market Cap
$215.34M
52W High
$4.60
52W Low
$1.35
ADV30
968,180
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -22,869,000 | -31,630,000 | 126,094,000 | 6,803,000 | 93,081,000 |
| Mar 2026 | 0 | — | -21,181,000 | -39,025,000 | 146,667,000 | 6,152,000 | 101,903,000 |
| Dec 2025 | 0 | — | -21,484,000 | -10,447,000 | 169,009,000 | 22,808,000 | 87,924,000 |
| Sep 2025 | 0 | — | -19,070,000 | -17,459,000 | 129,857,000 | 3,669,000 | 94,497,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-68,893,000
Investing CF
$12,857,000
Financing CF
$53,692,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-440,228,000
Inventory
—
Receivables
$583,000
ST Investments
$104,937,000
EBIT TTM
$-86,468,000
Pretax Income TTM
$-78,112,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,251,000 | -45,617,000 | 169,009,000 | 87,924,000 | 81,085,000 | -62,341,000 |
| Dec 2024 | 0 | -70,577,000 | -36,184,000 | 177,405,000 | 114,959,000 | 62,446,000 | -47,271,000 |
| Dec 2023 | 0 | -43,000,000 | -116,537,000 | 89,066,000 | 81,858,000 | 7,208,000 | -39,527,000 |
| Dec 2022 | 0 | -39,780,000 | -87,966,000 | 92,793,000 | 8,610,000 | 84,183,000 | -28,424,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.77
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $2.64 · call oi: 6,534 · put oi: 371
Expected Move to 2026-11-20:
±$0.88
(33.14%) —
implied range
$1.77 –
$3.52
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics, Inc. | $213.21M | $3.74 | — |
| SLGL | Sol-Gel Technologies Ltd. | $218.87M | $66.85 | — |
| NGEN | NERVGEN PHARMA CORP. | $208.59M | $1.94 | — |
| FHTX | Foghorn Therapeutics Inc. | $207.85M | $3.50 | — |
| RNAC | Cartesian Therapeutics, Inc. | $224.19M | $7.41 | — |
News headlines (Yahoo Finance, 1h cache)
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
2026-09-09 11:00 · Yahoo
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-13 20:05 · Yahoo
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
2026-06-25 11:00 · Yahoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
2026-06-22 11:00 · Yahoo
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
2026-06-08 11:00 · Yahoo
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
2026-05-27 11:55 · Yahoo
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:05 · Yahoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
2026-04-30 12:15 · Yahoo
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money
2026-04-20 14:14 · Yahoo
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
2026-07-08 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.